RxDoctor Payments Data

Christopher Mitchell, MD

Neurology · Jackson, TNNPI 1932317880

Payments from drug & device makers

$4,815in general payments, 2019–2025

Across 311 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$503
  • Bristol Myers Squibb$368
  • AstraZeneca$353
  • Sunovion Pharmaceuticals Inc.$258
  • SK Life Science, Inc.$223
  • plus $2K from 37 others

What the payments were for

  • Speaking & faculty fees$160%
  • Food & beverage$4,78699%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,815 in reported general payments places this provider in the 55th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$16,376
Medicare patients
117
Services billed
543

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate41$208,140
IngrezzaValbenazine Tosylate16$144,541
Aimovig AutoinjectorErenumab-Aooe87$116,101
Teriflunomide11$95,471
VumerityDiroximel Fumarate11$94,961
Nurtec OdtRimegepant Sulfate57$71,743
Emgality PenGalcanezumab-Gnlm43$55,368
QuliptaAtogepant26$46,906
Dimethyl Fumarate13$37,611
NuedextaDextromethorphan Hbr/Quinidine12$25,256
Sumatriptan Succinate56$12,619
Rivastigmine45$10,771
Levetiracetam137$4,527
Lacosamide17$4,020
Carbidopa-LevodopaCarbidopa/Levodopa99$3,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$135$208,14041 claims
Neurocrine Biosciences, Inc.Ingrezza$76$144,54116 claims
BiogenVumerity$45$94,96111 claims
PfizerNurtec Odt$56$71,74357 claims
AbbVieQulipta$1,152$46,90626 claims
Avanir Pharmaceuticals, Inc.Nuedexta$27$25,25612 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$147$3,06222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 361 neurology providers in Tennessee.

Other neurology in Jackson

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →